Julie McNairn, MD
Allergy · Ithaca, NYNPI 1982671442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,768 and has fallen 91.1% since, to $157 in 2025.
Across 120 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$620
- AstraZeneca$443
- Novartis$259
- Regeneron Healthcare Solutions, Inc.$233
- Amgen$225
- Pfizer$207
- plus $927 from 15 others
What the payments were for
- Food & beverage$2,914100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $620 |
| AstraZeneca | 16 | $443 |
| Novartis | 12 | $259 |
| Regeneron Healthcare Solutions, Inc. | 7 | $233 |
| Amgen | 10 | $225 |
| Pfizer | 7 | $207 |
| CSL Behring | 11 | $191 |
| Merck | 4 | $150 |
| Optinose US, Inc. | 2 | $119 |
| Sanofi | 5 | $84 |
| Bayer | 1 | $69 |
| Shire North American Group Inc | 4 | $57 |
| Pharming Healthcare, Inc. | 2 | $45 |
| Boehringer Ingelheim | 3 | $43 |
| Greer Laboratories, Inc. | 1 | $38 |
| Ionis Pharmaceuticals, Inc. | 1 | $34 |
| Genentech USA, Inc. | 2 | $26 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,914 in reported general payments places this provider in the 55th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 120 | $87,576 |
| Fasenra PenBenralizumab | 14 | $79,316 |
| XolairOmalizumab | 22 | $59,919 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $23,311 |
| Spiriva RespimatTiotropium Bromide | 23 | $21,244 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $17,056 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $14,345 |
| BreynaBudesonide/Formoterol Fumarate | 27 | $10,411 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $9,541 |
| QnaslBeclomethasone Dipropionate | 17 | $7,648 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $6,850 |
| DuleraMometasone/Formoterol | 11 | $4,918 |
| Arnuity ElliptaFluticasone Furoate | 26 | $4,608 |
| Epinephrine | 13 | $3,316 |
| Desloratadine | 39 | $2,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $620 | $115,494192 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $443 | $31,40159 claims |
| Boehringer IngelheimSpiriva Respimat | $43 | $21,24423 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $17 | $7,64817 claims |
| MerckDulera | $150 | $4,91811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 allergy providers in New York.
Other allergy in Ithaca
- Elliot RubinsteinIthaca$640
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.